Poster sessions at WCLC 2026 detail how surgery, nursing, and pathology can contribute to the multidisciplinary care of patients with lung cancer.
|Videos|June 11, 2019
Dr. Farago on Trilaciclib for Myelosuppression in Previously Treated Extensive-Stage SCLC
Author(s)Anna F. Farago, MD, PhD
Cancer Network spoke with Anna F. Farago, MD, of Massachusetts General Hospital, about the effect of trilaciclib on myelosuppression in patients with previously treated extensive-stage small-cell lung cancer receiving topotecan.
Advertisement
Cancer Network spoke with Anna F. Farago, MD, medical oncologist at Massachusetts General Hospital, about the effect of trilaciclib, a CDK 4/6 inhibitor, on myelosuppression in patients with previously treated extensive-stage small-cell lung cancer receiving topotecan. The results (
Advertisement
Related to this article
Medical oncologists, clinical pharmacists, and oncologic nurse practitioners share the presentation topics to look out for at WCLC 2026.
Advertisement
Advertisement
Trending on CancerNetwork
1
Lutetium Lu 177 Dotatate Biosimilar Earns Final FDA Approval in GEP-NETs
2
PANXEON Liquid Biopsy Demonstrates Potential for Detecting Early Pancreatic Cancer
3
Rusfertide Earns Category 1 NCCN Recommendation in Polycythemia Vera
4
AdenoVerse Platform Receives FDA Designation for HPV-Associated Cancers
5